---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036876"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:17:39.374678+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer

## Summary
- Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.
- Sven Guenther, Ph.D., Chief Scientific Officer, departing Zevra effective Dec. 23, 2024.
- Development and scientific functions consolidated under Chief Medical Officer Adrian Quartel, M.D.
- In-house drug discovery discontinued; laboratory facilities in Iowa and Virginia to close.
- Changes include elimination of positions in CMC and Clinical Development as part of strategic plan.

## SEC filing metadata
- accession: 0001437749-24-036876
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924036876/0001437749-24-036876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924036876/zvra20241204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036876
- JSON: https://secwatch.observer/filing/0001437749-24-036876.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.